Stereotaxis Ord Stock Price, News & Analysis

Stereotaxis (NYSE: STXS) and MicroPort EP announced that China's National Medical Products Administration (NMPA) has approved the Genesis RMN® System. This approval enables the commercialization of advanced robotic technology for minimally-invasive procedures in China. MicroPort EP will lead the commercial launch through its existing electrophysiology sales teams. The approval is part of a broader collaboration between both companies, announced in August 2021, which includes development and integration of robotic systems, navigated catheters, and MicroPort EP's Columbus™ 3D mapping system. The Genesis system, already FDA-cleared and CE-marked, has been used to treat thousands of patients in the US and Europe.

Stereotaxis (NYSE: STXS) announced that Hospital da Luz in Lisbon, Portugal has successfully implemented and treated its first patients using the Genesis Robotic Magnetic Navigation (RMN) System. Hospital da Luz Lisboa, part of Portugal's largest health group Luz Saude, is a university hospital that has performed over 4,000 robotic cardiac ablation procedures. The Genesis System represents the latest advancement in Robotic Magnetic Navigation technology, designed to treat arrhythmias through minimally invasive cardiac ablation procedures with robotic precision and safety.

Stereotaxis (NYSE: STXS) reported Q3 2024 financial results with total revenue of $9.2 million, up 18% year-over-year. System revenue was $4.4 million and recurring revenue was $4.8 million. The company achieved CE Mark for GenesisX robotic system and expects European CE Mark approval for MAGiC ablation catheter soon. Gross margin was 45%, with operating loss of $6.3 million. The quarter saw partial revenue recognition of three Genesis systems and orders for two additional systems. Cash balance stood at $11.0 million as of September 30, 2024, increasing to $13.3 million by end of October, with no debt.

Stereotaxis (NYSE: STXS) announced that the University of Kansas Health System has successfully implemented and treated its first patients using the Genesis Robotic Magnetic Navigation (RMN) System. The Genesis System represents the latest advancement in robotic technology for cardiac ablation procedures, treating arrhythmias with robotic precision and safety. Dr. Seth Sheldon, Cardiac Electrophysiologist at the facility, highlighted how the system's precision and stability enable delivery of personalized treatments, improving patient outcomes and quality of life. The technology has been used to treat over 150,000 patients globally.

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, announced it will release its 2024 third quarter financial results on November 11, 2024, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss results and corporate developments. Stereotaxis technology has been used to treat over 150,000 patients globally across the United States, Europe, Asia, and other regions.

Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, announced its participation in the Society for Cardiac Robotic Navigation's Annual Meeting on October 28-29 in Lisbon, Portugal. The conference will feature over forty physicians from across the globe, showcasing Stereotaxis' robotic technologies in presentations, panels, and demonstrations.

Key topics include:

• Artificial intelligence and robotic automation in cardiology
• Clinical experience with the MAGiC ablation catheter and Abbott's EnSite X mapping system
• Robotic catheter innovations for high-density mapping and pulsed field ablation
• Advancements in Genesis and GenesisX robotic systems
• Alternative access techniques from the arm
• Best practices for robotics in complex arrhythmia treatment

David Fischel, Stereotaxis Chairman and CEO, expressed excitement about the conference, noting the growing importance of robotics in advancing cardiology.

Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, has announced its participation in two upcoming investor conferences. David Fischel, Chairman and CEO, will represent the company at both events:

1. H.C. Wainwright 26th Annual Global Investment Conference on September 11th, 2024, where he will present a company overview at 12:30 pm EST and be available for one-on-one meetings.

2. Lake Street 8th Annual Best Ideas Growth Conference on September 12, 2024, where he will be available for one-on-one meetings.

Fischel expressed appreciation for the opportunity to share Stereotaxis' ongoing technological, commercial, and strategic progress with investors. Interested parties can arrange meetings through conference registration.

Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, announced its technology will be featured at the upcoming HRX digital health conference from September 5-7, 2024, in Atlanta. The conference, initiated by the Heart Rhythm Society, focuses on digital technologies advancing cardiovascular medicine.

CEO David Fischel will participate in two key sessions:

• A roundtable discussion on "The EP Lab of the Future" on September 5th at 4:45 PM EDT
• A joint session on "The Role of Robotics in Present and Future Care of Heart Rhythm Patients" on September 6th at 9:45 AM EDT

These sessions underscore the growing importance of robotic technology in improving patient outcomes and advancing cardiac rhythm management.

Stereotaxis (NYSE: STXS) reported its 2024 Q2 financial results, highlighting strategic progress despite commercial challenges. Key achievements include CE mark approval for GenesisX in Europe, 510(k) submission in the US, and progress on MAGiC regulatory reviews. The company also completed the acquisition of Access Point Technologies.

Q2 revenue was $4.5 million, down from $7.9 million in Q2 2023. System revenue was $0.2 million, while recurring revenue was $4.3 million. The gross margin was 74%. Operating expenses were $9.3 million, including $2.5 million in non-cash stock compensation. The company reported an operating loss of $6.0 million and a net loss of $5.8 million. Stereotaxis ended the quarter with $15.2 million in cash and no debt.